PMID- 29180168
OWN - NLM
STAT- MEDLINE
DCOM- 20190129
LR  - 20220331
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 269
DP  - 2018 Jan 10
TI  - Inhalable particulate drug delivery systems for lung cancer therapy: 
      Nanoparticles, microparticles, nanocomposites and nanoaggregates.
PG  - 374-392
LID - S0168-3659(17)31032-5 [pii]
LID - 10.1016/j.jconrel.2017.11.036 [doi]
AB  - There is progressive evolution in the use of inhalable drug delivery systems 
      (DDSs) for lung cancer therapy. The inhalation route offers many advantages, 
      being non-invasive method of drug administration as well as localized delivery of 
      anti-cancer drugs to tumor tissue. This article reviews various inhalable 
      colloidal systems studied for tumor-targeted drug delivery including polymeric, 
      lipid, hybrid and inorganic nanocarriers. The active targeting approaches for 
      enhanced delivery of nanocarriers to lung cancer cells were illustrated. This 
      article also reviews the recent advances of inhalable microparticle-based drug 
      delivery systems for lung cancer therapy including bioresponsive, large porous, 
      solid lipid and drug-complex microparticles. The possible strategies to improve 
      the aerosolization behavior and maintain the critical physicochemical parameters 
      for efficient delivery of drugs deep into lungs were also discussed. Therefore, a 
      strong emphasis is placed on the approaches which combine the merits of both 
      nanocarriers and microparticles including inhalable nanocomposites and 
      nanoaggregates and on the optimization of such formulations using the proper 
      techniques and carriers. Finally, the toxicological behavior and market potential 
      of the inhalable anti-cancer drug delivery systems are discussed.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Abdelaziz, Hadeer M
AU  - Abdelaziz HM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Gaber, Mohamed
AU  - Gaber M
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt.
FAU - Abd-Elwakil, Mahmoud M
AU  - Abd-Elwakil MM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt.
FAU - Mabrouk, Moustafa T
AU  - Mabrouk MT
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Elgohary, Mayada M
AU  - Elgohary MM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Kamel, Nayra M
AU  - Kamel NM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Kabary, Dalia M
AU  - Kabary DM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt; Department of 
      Pharmaceutics, Faculty of Pharmacy, Pharos University at Alexandria (PUA), 
      Alexandria, Egypt.
FAU - Freag, May S
AU  - Freag MS
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Pharmaceutics, Faculty of 
      Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Samaha, Magda W
AU  - Samaha MW
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Mortada, Sana M
AU  - Mortada SM
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Elkhodairy, Kadria A
AU  - Elkhodairy KA
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
FAU - Fang, Jia-You
AU  - Fang JY
AD  - Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung 
      University, Taoyuan 333, Taiwan; Research Center for Industry of Human Ecology 
      and Research Center for Chinese Herbal Medicine, Chang Gung University of Science 
      and Technology, Kweishan, Taoyuan 333, Taiwan; Department of Anesthesiology, 
      Chang Gung Memorial Hospital, Kweishan, Taoyuan 333, Taiwan. Electronic address: 
      fajy@mail.cgu.edu.tw.
FAU - Elzoghby, Ahmed O
AU  - Elzoghby AO
AD  - Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria 
      University, Alexandria 21521, Egypt; Department of Industrial Pharmacyx, Faculty 
      of Pharmacy, Alexandria University, Alexandria 21521, Egypt. Electronic address: 
      ahmed_elzoghby@alexu.edu.eg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171124
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Administration, Inhalation
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Nanostructures/*administration & dosage
OTO - NOTNLM
OT  - Lung cancer
OT  - Microparticles
OT  - Nanoaggregates
OT  - Nanocarriers
OT  - Nanocomposites
OT  - Nanotoxicology
OT  - Pulmonary drug delivery
EDAT- 2017/11/29 06:00
MHDA- 2019/01/30 06:00
CRDT- 2017/11/29 06:00
PHST- 2017/10/06 00:00 [received]
PHST- 2017/11/21 00:00 [revised]
PHST- 2017/11/21 00:00 [accepted]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2019/01/30 06:00 [medline]
PHST- 2017/11/29 06:00 [entrez]
AID - S0168-3659(17)31032-5 [pii]
AID - 10.1016/j.jconrel.2017.11.036 [doi]
PST - ppublish
SO  - J Control Release. 2018 Jan 10;269:374-392. doi: 10.1016/j.jconrel.2017.11.036. 
      Epub 2017 Nov 24.